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Abstract
Background: Antibodies that impair Plasmodium falciparum merozoite invasion and intraerythrocytic development are one
of several mechanisms that mediate naturally acquired immunity to malaria. Attempts to correlate anti-malaria antibodies
with risk of infection and morbidity have yielded inconsistent results. Growth inhibition assays (GIA) offer a convenient
method to quantify functional antibody activity against blood stage malaria.
Methods: A treatment-time-to-infection study was conducted over 12-weeks in a malaria holoendemic area of Kenya.
Plasma collected from healthy individuals (98 children and 99 adults) before artemether-lumefantrine treatment was tested
by GIA in three separate laboratories.
Results: Median GIA levels varied with P. falciparum line (D10, 8.8%; 3D7, 34.9%; FVO, 51.4% inhibition). The magnitude of
growth inhibition decreased with age in all P. falciparum lines tested with the highest median levels among children
,4 years compared to adults (e.g. 3D7, 45.4% vs. 30.0% respectively, p=0.0003). Time-to-infection measured by weekly
blood smears was significantly associated with level of GIA controlling for age. Upper quartile inhibition activity was
associated with less risk of infection compared to individuals with lower levels (e.g. 3D7, hazard ratio=1.535, 95%
CI=1.012–2.329; p=0.0438). Various GIA methodologies had little effect on measured parasite growth inhibition.
Conclusion: Plasma antibody-mediated growth inhibition of blood stage P. falciparum decreases with age in residents of a
malaria holoendemic area. Growth inhibition assay may be a useful surrogate of protection against infection when outcome
is controlled for age.
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Introduction
Epidemiological evidence shows that people living in Plasmodium
falciparum malaria holoendemic areas who experience repeated or
chronic blood stage parasitemia develop clinical immunity with
increasing age [1]. This naturally acquired immunity is in part due
to antibodies elicited in response to infection since passive transfer
of sera from clinically immune African adults to malaria-infected
children decreases the level of blood stage malaria coincidental
with reduced symptoms [2,3]. The mechanisms by which such
antibodies protect against parasitemia are complex and have been
suggested to include i) inhibition of erythrocyte invasion and
growth by antibodies directed against proteins expressed by
merozoites and subsequent intraerythrocytic developmental stages
of the parasite [4]; ii) antibody-dependent mononuclear cell
cytokine-mediated inhibition of intraerythrocytic parasite growth
directed by antibodies to a limited set of antigens [5,6]; and iii)
sequestration and phagocytosis of malaria-infected erythrocytes in
the spleen mediated by antibodies to parasite antigens expressed
on the erythrocyte surface [7–9]. Understanding the roles of anti-
malaria antibodies is important to advance knowledge of the
fundamental processes that underlie age-related acquired immu-
nity since repeated exposure to blood stage malaria has different
immunologic consequences compared to first or infrequent
malaria infection [10]. In addition, reproducible in vitro assays
of antibody-mediated malaria immunity are needed as surrogate
endpoints to inform clinical trials of blood stage vaccines that are
tested in malaria endemic populations [11–13].
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3557Previous studies of naturally occurring immunity have relied
primarily on serologic methods to measure antibodies to
recombinant malaria protein vaccine candidates, infected eryth-
rocytes, and parasite extract [14–22]. Observed inconsistencies
and the poor predictive value of these serologic assays for malaria
infection and morbidity may be related to the lack of compre-
hensive analysis of antibody responses to multiple blood stage
antigens, many of which may not be included in the assays
performed, and the likelihood that serology alone does not reflect
the functional activity of such antibodies, e.g. recombinant
proteins may have a conformation dissimilar to that of the native
protein. Evaluating the broad repertoire of functional antibodies to
blood stage malaria may also be useful in the future if attenuated
whole blood stage parasites are considered as a strategy to develop
a human malaria vaccine [23].
Growth inhibition assays (GIA) quantify the functional activity
of antibodies directed against multiple blood stage antigens by
measuring parasite growth in the presence of ‘‘immune’’ plasma
compared to ‘‘non-immune’’ plasma. GIA have been used in
vaccine development for merozoite antigens to assess the
relationship of antibody responses after immunization to the time
and level of parasitemia following challenge infection in monkeys
[24–26]. Vaccine trials of Apical Membrane Antigen-1 (AMA-1)
and Merozoite Surface Protein-1 (MSP-1) in malaria naı ¨ve human
volunteers have elicited high antibody titers with increased
parasite growth inhibitory antibody activity but have not been
correlated with protection (Spring et al, manuscript in preparation,
Bergmann-Leitner et al, manuscript in preparation). Studies of
persons with naturally acquired malaria immunity have shown an
inconsistent relationship between serologic and functional anti-
body responses [17,27]. Blood stage antigen (AMA-1 and MSP-1)
vaccine studies in malaria experienced individuals demonstrate
variable serologic and functional antibody responses, depending
on the antigen tested [13,28,29]. Vaccine efficacy as related to
GIA has been observed in animal models but not yet in humans.
Logistical impediments to the use of GIA in large scale
population-based field studies have included the limited volume
of blood that can be obtained from research participants,
particularly children and infants, and time consuming determina-
tion of parasite growth endpoints. These logistical issues have in
large measure been overcome [30–34]. In this study we used
several methodologies from different laboratories to examine
whether GIA could be used as a surrogate of protection against
blood stage infection in children and adults living in a malaria
holoendemic area of western Kenya.
Methods
Study population and study design
After community information sessions explaining the objectives
of the research to understand the immune mechanisms underlying
acquired resistance, assent and informed consent for enrolment
and participation in the study was obtained from 117 healthy
individuals (98 children and 99 adults) who were residents of the
village of Kanyewegi, Nyanza Province, Kenya. The study took
place in July 2003, during a time of relatively high malaria
transmission. Previous studies from this area have shown that anti-
parasite and clinical immunity to malaria is acquired with
increasing age such that adult levels are attained by 10–14 years
[35]. The average age of children and adults participating in our
study was 7.7 and 39.4 years, respectively. Participants were
asymptomatic without fever and had normal age-adjusted
hemoglobin levels. Venous blood samples were collected prior to
directly observed consumption of age- and weight-appropriate 6-
dose regimens of CoArtemH (Artemether/Lumefantrin) regardless
of baseline infection status. At baseline, 72% of children and 48%
of adults had parasites present on peripheral blood smears. Weekly
finger prick blood samples were collected for 11 consecutive weeks
to determine time to infection by blood smear. All of the
individuals included in this analysis had negative blood smears by
microscopy two weeks post-treatment. Ethical approval for human
investigation was obtained from the Institutional Review Board at
Case Western Reserve University, University Hospital of Cleve-
land and the Ethical Review Committee at the Kenya Medical
Research Institute. Adults participants signed a consent form in
English or Duhluo (the local language); parents or guardians
signed in the case of minors ,18 years.
Blood smear examination
Thick and thin blood smears (BS) were prepared, fixed in 100%
methanol, stained with 5% Giemsa solution and examined by light
microscopy for infected erythrocytes as described previously [36].
Growth Inhibition Assays
Selected assays were performed with all 197 plasma samples,
and all assays were performed with an identical subset of 54
plasma samples in three different laboratories using their standard
procedures. The subset of 54 plasma samples was chosen to
evaluate MSP-142 specific antibody responses and T cell responses
as they related to age. The subset contained equal numbers of
adults (average age 50 years) and children (average age 5.8 years),
and both groups contained equal numbers of MSP-142 responders
and non-responders. Power calculations indicated a sample size of
12 for each group was needed resulting in the subset of 54
(Moormann, manuscript in preparation). Plasma volume was not a
limiting factor as all individuals had venous blood draws with
several mL of plasma collected. Plasma samples were tested
individually. No Kenyan plasma samples were pooled for any
assay. For ease of description, the methods are described by
laboratory location: CWRU=Case Western Reserve University,
WEHI=Walter and Eliza Hall Institute, WRAIR=Walter Reed
Army Institute of Research. Table 1 summarizes the GIA assays
performed with the subset of 54 samples.
CWRU. D10 parasites (D10-PfM3’ [37]) were utilized and
plasma was not dialyzed. Ring-stage parasites were synchronized
twice by sorbitol lysis (5% D-sorbitol (Sigma, St. Louis, MO)) and
allowed to mature to late trophozoite/schizont stages. Parasites
were cultured at 4% hematocrit in RPMI-1640 supplemented with
25 mg/mL HEPES, 2 mg/mL sodium bicarbonate, 0.5%
Albumax II (Gibco, Grand Island, NY), 2.4 mM L-glutamine,
0.08 mg/ml gentamicin, and 0.2 mM hypoxanthine. Cultures
were maintained at 37uC in an atmosphere of 5% CO2,1 %O 2
and 94% N2. Parasites were adjusted to 0.5% infected red cells
with a final 2% hematocrit, 1:10 plasma dilution, and 100 mL final
volume in 96-well flat-bottom microtiter plates. The cultures were
incubated for 26 hours to allow for schizont rupture and
merozoite invasion (monitored by microscopy to ensure full
schizont rupture). 25 mL of resuspended cultures were removed,
fixed with 0.25% gluteraldehyde in PBS for 45 minutes, and
placed in 1 mg Hoechst 33342 (HO) stain (Molecular Probes,
Eugene, OR) in 400 mL1 6PBS for .24 hours at 4uC [38,39]).
Stained cells were examined with a BD LSR II flow cytometer to
collect data from a minimum of 5610
4 cells. Becton-Dickinson
FACS Diva 5.01 was used to collect and FlowJo 8.5.1 to analyze
cytometry data. Where indicated, 106SYBR Green I (Molecular
Probes, Eugene, OR) instead of HO was used to stain fixed cells.
Parasitemia was recorded as the number of infected erythrocytes.
The mean parasitemia for duplicate wells was used to determine
Acquired Immunity to Malaria
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plasma parasitemia/non-immune plasma parasitemia6100).
Plasma samples from four North Americans who had never
been exposed to malaria were pooled as the ‘‘non-immune’’
plasma controls.
WEHI. D10 (D10-PfM3’ [37]) and 3D7 parasites were
utilized. Test plasma was dialyzed against PBS using 50-kDa-
molecular-weight cutoff dialysis tubes (2051; Chemicon,
Temecula, CA) and concentrated to the original starting volume
using centrifugal concentration tubes (100-kDa MWCO; Pall
Corp, Ann Arbor, MI) [34,40].
D10 parasites (D10-PfM3’ [37]) were transfected to express a
green fluorescent protein (GFP) to facilitate detection by flow
cytometry (Wilson, Crabb, and Beeson, manuscript in prepara-
tion). Parasites were cultured and assays performed as previously
described [34]. Briefly, a synchronous late trophozoite parasite
suspension of 0.4% with a final 2% hematocrit was cultured with a
final plasma dilution 1:10 in a final volume of 100 mL using U-
bottom 96-well plates. The assay was harvested at two time points,
after one and two cycles of parasite growth. This was
accomplished by incubating the cultures for 26 hours to allow
for schizont rupture and merozoite invasion (ring stage, monitored
by microscopy). Then 20 mL of resuspended cultures were
removed, fixed with 0.25% gluteraldehyde for 45minutes, placed
in 106 SYBR Green I stain, and stored at 4uC [41]. After an
additional 24 hours of culture, 35 mL media were added to each
well. After a total of 96 hours of culture (two cycles of growth,
trophozoite stage) the cultures were resuspended and GFP was
detected using a FaCSCalibur flow cytometer.
GIA utilizing 3D7 parasites was performed using a parasite
suspension of 0.1% with a final 2% hematocrit was cultured with a
final plasma dilution 1:10 in a final volume of 100 mL using U-
bottom 96-well plates. The cultures were incubated for a total of
96 hours of culture (2 cycles of growth until trophozoite stage,
monitored by microscopy) at which time 3D7 parasite containing
wells were stained with 100 mLo f1 0mg/ml ethidium bromide
(Bio-Rad, Hercules, CA) in PBS for 1 hour [34]. Parasitemia was
assessed using a FaCSCalibur flow cytometer. The mean
parasitemia for duplicate wells was used to determine growth
inhibition calculated as described above.
WRAIR. 3D7 and FVO parasites were utilized. Test plasma
was dialyzed against PBS followed by RPMI using 12-kDa
MWCO [42] and heat-inactivated. The GIA was performed as
previously described [31,32] with synchronized schizonts and a
starting parasitemia of 0.3% in 384-well flat-bottom plates with a
final hematocrit of 2% in a final volume of 20 mL. The assays were
cultured for one cycle with harvest at late trophozoite stage (i.e.,
40 hours for 3D7, 48 hours for FVO). Cells were harvested and
parasite lactic dehydrogenase (pLDH) was measured and detected as
previously described [43]. The mean parasitemia for triplicate wells
wasusedtodeterminegrowthinhibitioncalculatedusingthefollowing
equation: {12([ODtest plasma2ODRBC]/[ODnon-immune serum
2ODRBC])}6100. Non-immune serum pool of .5 individual sera
o b t a i n e df r o mt h eI n t e r s t a t eB l o o d b a n kT e n n e s s e ew a su s e da s‘ ‘ n o n -
immune’’ controls.
Statistical analyses
Adults were defined as .14 years of age. Continuous variables
were compared using Mann-Whitney, Spearman’s rho, and
Kruskal-Wallis tests. Inter-assay comparison of results were
evaluated using Wilcoxon signed rank test, Bland-Altman plots
to describe the equivalence of paired results [44], and the
McNemar test to assess the differences in the proportion of
responders (defined as .15% growth inhibition) vs. non-
responders in paired assays. Kaplan Meier and Cox proportional
hazards regression were used to compare time to infection across
groups stratified by upper quartile vs. lower quartiles GIA
responders. The assumption of proportionality was tested using
plots of hazard functions and residuals. Analyses were conducted
using SAS Version 8.2 (Carey, NC) and GraphPad Prism 4.
Results
Plasma exhibits parasite specific growth inhibition in GIA
Plasma samples from 197 Kenyan adults and children were
tested with various GIA against three different laboratory-adapted
lines. The D10 GIA was performed at CWRU while the 3D7 and
FVO GIA were performed at WRAIR. Plasma samples demon-
strated more inhibitory activity against FVO (median 51.4%) than
3D7 (34.9%; p=0.0005, Mann-Whitney test) as shown in
Figure 1A. D10 GIA results are included in Figure 1A, but
because assay methodology for D10 GIA was different from 3D7
and FVO GIA, direct comparison of results cannot be made.
These assays utilized one cycle of parasite growth and comparable
methods of measuring parasitemia were used. These plasma
samples appear to have lower growth inhibition against D10
(median 8.8%) than 3D7 or FVO. Figure 1B demonstrates D10
and 3D7 GIA results with the subset of 54 plasma samples. These
GIA were performed at WEHI using 2 cycles of parasite growth
with parasitemia assessed by flow cytometry at the trophozoite
stage. In these experiments, plasma samples demonstrated more
inhibitory activity against 3D7 (median 52.6%) than D10 (median
18.5%; p,0.0001, Mann-Whitney). Growth inhibition levels are
higher in these experiments compared to those conducted with all
Table 1. Summary of GIA methodologies performed with 54 Kenyan plasma samples.
Parasite line
# of growth
cycles Stage harvested
Method of parasitemia
measurement Plasma dialyzed Location GIA performed
D10 1 Ring FACS (HO) No CWRU
D10 1 Ring FACS (SYBR) Yes WEHI
D10 2 Late Troph FACS (GFP) Yes WEHI
3D7 1 Late Troph pLDH Yes WRAIR
FVO 1 Late Troph pLDH Yes WRAIR
3D7 2 Late Troph FACS (EtBr) Yes WEHI
HO=Hoechst 33342, Troph=trophozoite, pLDH=parasite lactic dehydrogenase, SYBR=SYBR Green I, GFP=green fluorescent protein, EtBr=Ethidium Bromide.
CWRU=Case Western Reserve University, WRAIR=Walter Reed Army Institute of Research, WEHI=Walter and Eliza Hall Institute
doi:10.1371/journal.pone.0003557.t001
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growth cycles [34]. From these data we conclude that the same
plasma samples exhibit different levels of growth inhibition with
different parasite lines. Plasma samples exhibiting growth
inhibition against 3D7 also tended to exhibit growth inhibition
against FVO (Pearson correlation r
2=0.763). The rank order
magnitude of growth inhibition mediated against each parasite line
was not consistent among individual plasma samples (Figure 2).
Growth inhibitory activity decreases with age
The median level of growth inhibition was consistently greater
for plasma from children than adults (Figure 3) regardless of
parasite line, assay conditions and methods of measuring
parasitemia (Mann-Whitney test: D10 p,0.0001, 3D7
p=0.0003, and FVO p=0.0087). To characterize the relationship
between age and growth inhibitory activity, the 98 plasma samples
from children were divided into three age groups; 1–4, 5–9, and
10–14 years. Note that the youngest child participating in this
study was 15 months, and only two participants were less than
2 years. Thus, immune responses in children examined here were
not affected by maternal antibodies which wane by age 9–12
months [45]. Growth inhibitory activity decreased progressively
with each age group for all parasite lines tested (Figure 4). The
youngest age group had significantly higher growth inhibition
compared to the other age groups with all parasite lines tested. For
D10 GIA, all age groups differed significantly from each other. For
3D7 and FVO GIA, the youngest age group differed significantly
from the other two age groups. The 5–9 and 10–14 year old group
GIA did not differ significantly from each other, though a
decreasing trend was apparent. No significant difference was
observed between the 10–14 year olds and adults. Additionally,
baseline malaria infection status, controlling for age, did not affect
GIA levels at a statistically significant level. However, a trend that
baseline BS negative children and adults had higher GIA than
baseline BS positive children and adults was seen especially in 3D7
and FVO GIA (Figure 5). A larger study population (we estimate
at least n=258 children and n=3912 adults for 3D7 GIA) would
be needed to observe a statistically significant difference in GIA
stratified by baseline BS status.
GIA is associated with increased time to malaria blood
stage infection
Using a time-to-infection study design to examine the relation
between growth inhibition in vitro and protection against blood
stage infection, weekly finger stick blood samples were examined
by microscopy for malaria parasites for the 11 weeks following
administration of anti-malarial drugs. To accommodate the
observation that the magnitude of growth inhibition differs among
the various parasites lines (Figure 1), positive cut-off values were
defined by the upper quartile of responders. Comparing high vs.
low functional antibody assay responders has previously been used
in Kaplan Meier analyses [46].
Time to infection was significantly associated with the degree of
growth inhibition. While the time to infection differed between
children and adults, the effect size (hazard ratios) were very similar
Figure 1. GIA of Kenyan plasma samples for various P.
falciparum lines. Panel A, box plot of GIA result distribution for
N=197 samples for each parasite line tested (D10, 3D7, and FVO).
Horizontal bars indicate the median percent growth inhibition. D10 GIA
was conducted with different methodology than that of 3D7 and FVO
GIA. All assays utilized one cycle of parasite growth and comparable
methods of measuring parasitemia. Plasma exhibited higher growth
inhibition against FVO than 3D7 (p=0.0005, Mann-Whitney test). Panel
B, box plot of GIA result distribution for N=54 samples for D10 and 3D7
GIA utilizing the same methodology. Horizontal bars indicate the
median percent growth inhibition. Plasma samples demonstrated more
inhibitory activity against 3D7 than D10 (p,0.0001, Mann-Whitney).
doi:10.1371/journal.pone.0003557.g001
Figure 2. GIA of 5 representative Kenyan samples tested in
parallel against 3 parasite lines (D10, 3D7 and FVO). Individual A
has significant inhibitory activity against the 3 lines tested whereas
individual D has essentially no inhibitory activity against all lines tested.
Individual B has a growth inhibition pattern that reflects that of the
entire population (Figure 1). Other individual samples demonstrate
variable growth inhibitory activity against the different lines tested.
doi:10.1371/journal.pone.0003557.g002
Acquired Immunity to Malaria
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HR=1.60, 95% CI=0.78–3.28 for adults.). Therefore, age was
treated as a confounder in these analyses as it was significantly
associated with time-to-infection and growth inhibition (p,0.001).
Individuals whose plasma was within the upper quartile of
growth inhibition experienced significantly less risk of infection
compared to individuals with lower levels for the 3D7 GIA (hazard
ratio=1.535, 95% CI=1.012–2.329; p=0.0438) and FVO GIA
(hazard ratio=1.600, 95% CI=1.014–2.526; p=0.0435). These
quartiles represented, respectively, positive growth inhibition cut-
off values of 60% and 75%, corresponding to 53% and 60% less
risk of infection.
Age remained an independent risk factor for infection in these
proportional hazards models of GIA. For example, the magnitude
of risk of infection decreased with each category of age from 1–
4 years, 5–9, and 10–14, relative to adults (hazard ratio=6.040
(3.719, 9.810); 4.160 (2.754–6.286); and 1.619 (0.897–2.923),
respectively) controlling for 3D7 GIA. Figure 6 further illustrates
that age is an essential feature of growth inhibition assessment.
The hazard ratio was not significantly different for D10 at the
upper quartile cutoff value (p=0.25). However, a difference was
observed among the 7% of individuals with the highest levels of
growth inhibition using D10 (hazard ratio=2.292, 95%
CI=1.009–5.208; p=0.0475). Just as baseline infection status
determined by positive BS had no effect on GIA levels controlling
for age, baseline infection status did not affect time to infection
controlling for age.
Various GIA methodologies have little effect on parasite
growth inhibition
Comparisons between GIA methods were undertaken to
differentiate the effects of dialysis, culture media, heat-inactivation
of plasma, flat vs. U-bottom tissue culture plates, number of
growth cycles examined, and parasitemia measurement modali-
ties. The same 54 plasma samples from the total 197 were
examined with all assays. We focused on three main methodolog-
ical disparities; 1) one vs. two growth cycles, 2) flow cytometry vs.
pLDH assessment of parasitemia, and 3) dialysis vs. no dialysis of
plasma. Method comparisons were made between GIA conducted
with the same parasite line using the preferred methodology of the
testing laboratory (summarized in Table 1). Inter-assay compar-
ison of results were evaluated using Wilcoxon signed rank test,
Bland-Altman plots to describe the equivalence of paired results
[44], and the McNemar test to assess the differences in the
proportion of responders (defined as .15% growth inhibition) vs.
non-responders. Bland-Altman and McNemar tests have been
shown to be superior to Spearman correlation tests (r
2) when
comparing assay results [31,44].
GIA results were affected by the number of growth cycles
parasites were permitted to complete (Figure 7A and B). Using
D10 parasites and flow cytometry to measure parasitemia, growth
inhibition was significantly greater with two cycles (96 hour
culture, median inhibition 18.5%) compared to one cycle (24 hour
culture, median inhibition 8.3%; p=0.0003, Wilcoxon signed-
rank test). A Bland-Altman plot shows a bias of 211.05, indicating
the two assays produce different results. Also, the difference in the
proportion of plasma donors classified as responders and non-
responders in the two assays was statistically different (p=0.006,
McNemar test). The increased growth inhibition with two growth
Figure 3. Box plot of GIA distribution for each parasite line tested (D10, 3D7, and FVO) divided by child (n=98) and adult (n=99).
Horizontal bars indicate the median % growth inhibition. The child and adult growth inhibition medians differ significantly from each other for each
parasite line tested (Mann-Whitney test). Child growth inhibition is consistently higher than adult growth inhibition for each parasite line tested.
doi:10.1371/journal.pone.0003557.g003
Figure 4. Box plot of GIA distribution for each parasite line
tested (D10, 3D7, and FVO) with only children’s plasma
samples (n=98) divided by age group: 1–4 years (n=28), 5–
9 years (n=48), and 10–14 years (n=22). The youngest age group
consistently had higher growth inhibition compared to children in older
age groups (Mann-Whitney test).
doi:10.1371/journal.pone.0003557.g004
Acquired Immunity to Malaria
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[34] and/or poorly characterized nutritional variables. Addition-
ally, parasite growth from one to two cycles in the presence of
human immune plasma could select for merozoite antigenic
variation that may affect parasite invasion efficiency [40,47–49]
Thus comparison of different GIA must take cycle number into
consideration.
GIA using 3D7 parasites performed with pLDH compared to
FACS to assess parasitemia revealed no difference between the
median growth inhibition levels for these two assays (pLDH,
48.4%; FACS, 52.6%; p=0.88, Wilcoxon signed-rank test).
Bland-Altman plots showed negligible bias (0.3), and the difference
in proportions of responders and non-responders was not
statistically different (p=0.99, McNemar test) (Figure 7C and
D). One important caveat is that pLDH was used to assess
parasitemia after one cycle of growth (48 hour culture) whereas the
FACS was used to assess parasitemia after two cycles (96 hour
culture). Similarities in results of the two assays despite the shorter
period of culture for the pLDH assay could be related to a wider
range of responses for pLDH assay and therefore lower sensitivity
compared to FACS [34]. We believe that flow cytometry using
DNA stains [32,38] is preferable to pLDH because of greater
sensitivity [34] and to microscopy because of the capacity to
evaluate greater numbers of infected erythrocytes with no observer
bias.
Dialysis of plasma had no effect on the level of growth inhibition
in this population of healthy asymptomatic Kenyans. GIA using
FACS and D10 parasites at one growth cycle resulted in median
growth inhibition of 8.3% and 9.1% for dialyzed and non-dialyzed
plasma samples respectively (p=0.165, Wilcoxon signed-rank
test). Bland-Altman plots showed minimal bias (22.8) and the
difference in proportion of responders and non-responders was not
statistically different (p=0.40, McNemar test) (Figure 7E and F).
Earlier studies confirmed that dialysis can effectively remove
common antimalarials from plasma [34]. Others have attempted
to avoid dialysis by using drug resistant parasites [50]. Indeed, the
D10 PfM3’ line used here contains a drug resistant cassette [37].
Since it is not possible to exclude definitively the presence of anti-
malarial drugs or other non-antibody inhibitors, our recommen-
dation is that standardized GIA include prior dialysis of plasma.
Furthermore, well shape (flat vs. U-bottom), heat-inactivation of
plasma, and different media components did not have an effect on
growth inhibitory levels (data not shown). In sum, little difference
in growth inhibition according to GIA method was appreciated
beyond growth cycle number.
Discussion
Antibodies that impair merozoite invasion and subsequent
development of parasites in erythrocytes are one of several
mechanisms by which persons who experience repeated malaria
exposure during childhood are thought to acquire protection
against high-density parasitemia and symptomatic infection later
in life [4]. We compared in this study various GIA methodologies
from three different laboratories and evaluated GIA results as
potential immunologic surrogates of protection against blood stage
infection in children and adults living in a malaria holoendemic
area of Kenya.
Figure 5. Box plot of GIA distribution of 197 plasma samples stratified by BS status at baseline and age for each parasite line
examined (D10, 3D7, FVO). BS- children (n=17), BS+ children (n=81), BS2 adults (n=66) and BS+ adults (n=33). No statistical
difference was detected between any comparison groups (ie. BS2 children vs. BS+ children with D10 GIA; Mann-Whitney test). A trend that BS2
groups had higher growth inhibition than BS+ groups was observed. P values of visually dissimilar pairs are included.
doi:10.1371/journal.pone.0003557.g005
Figure 6. Relationship of growth inhibition with time to
infection. Time to infection in individuals with upper quartile GIA
results (.60% inhibition) tested against 3D7 compared to lower
quartiles GIA results (,60% inhibition) controlling for age (Cox
regression, p=0.0438). Kaplan-Meier curves are divided by child and
adult to illustrate age effects on growth inhibition. Similar analyses
controlling for age were performed with D10 and FVO GIA.
doi:10.1371/journal.pone.0003557.g006
Acquired Immunity to Malaria
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samples to compare one growth cycle (harvest at ring stage) to two growth cycles (harvest at trophozoite stage). Parasitemia was assessed by flow
cytometry (106SYBR Green 1 stain for one cycle, GFP for two cycles). Two growth cycles of D10 GIA had a statistically significant higher median
inhibition (18.5% inhibition) compared to one cycle D10 GIA (8.3% inhibition; p=0.0003; Wilcoxon signed-rank test). Panel B shows the Bland-
Altman plot to assess the degree of agreement between paired results after one vs. two growth cycles. The points display the difference in growth
inhibition between the two assays (y-axis) against their corresponding average values (x-axis). The horizontal lines correspond to the mean difference
(solid line) 62SD (dashed lines). The mean shows a bias of -11.05, indicating the two assays are producing different results with a trend of increasing
differences with increased averages. Panel C depicts box plots for 3D7 GIA using the same 54 Kenyan samples. All samples were dialyzed prior to
use. 3D7 GIA using one cycle of parasite growth, harvest at the trophozoite stage with parasitemia measured by pLDH was compared to 3D7 GIA
using two growth cycles, harvest at the trophozoite stage with parasitemia measured by flow cytometry (EtBr). No statistically significant difference
was noted (Wilcoxon signed-rank test). Panel D shows the Bland-Altman plot to assess the degree of agreement between paired assay results. The
points display the difference in growth inhibition between the two assays (y-axis) against their corresponding average values (x-axis). The horizontal
lines correspond to the mean difference (solid line) 62SD (dashed lines). Panel E depicts box plots for D10 GIA using the same 54 Kenyan samples
either dialyzed or not dialyzed. GIA was performed using one cycle of parasite growth (harvest at ring stage) followed by flow cytometry to measure
parasitemia (SYBR Green 1 stain for dialyzed samples, Hoechst stain for non dialyzed samples). No statistically significant difference was noted
(Wilcoxon signed-rank test). Panel F shows the Bland-Altman plot to assess the degree of agreement between paired assay results. The points
display the difference in growth inhibition between the two assays (y-axis) against their corresponding average values (x-axis). The horizontal lines
correspond to the mean difference (solid line) 62SD (dashed lines). The mean has minimal bias (22.8) with a small trend of increasing differences
with increased averages.
doi:10.1371/journal.pone.0003557.g007
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growth inhibition decreased with age in all parasite lines tested,
regardless of assay methodology. Indeed, the age-related decrease
in growth inhibition parallels age-related decrease in the
prevalence of high density parasitemia [35]. This inverse
correlation between growth inhibition and age is counterintuitive
when considered in the context of other studies showing that
antibody prevalence and titers to blood stage antigens measured
by serology increase with age [15,51–57]. The data presented here
thus underscore the notion that serologic and functional
measurements of antibodies directed against merozoite pathways
involved in invasion and intra-erythrocytic growth may be
incongruent in persons with naturally acquired immunity, as
demonstrated previously for antibodies to single antigens such as
the C-terminal region of MSP-1 [46,58]. It is not yet known why
increasing age is associated with reduced overall growth inhibitory
antibodies in our study population, but similar results are also
reported by McCallum et al [59]. We speculate that single or few
malaria infections may generate low-complexity ‘‘mono-specific’’
antibody responses directed against selected antigenic domains of
merozoite ligands that are functionally critical to invasion, akin to
the situation when malaria-naı ¨ve individuals are vaccinated with
single candidate antigens [11,12]. In contrast, the multiple
infections experienced with increasing age in high malaria
transmission areas may generate a more complex antibody
repertoire, including a subset of antibodies that interfere with or
impair functional inhibitory activity. Additionally, IgM antibodies
that characterize early infections may have greater functional
inhibitory activity than IgG antibodies which are predominant
after greater numbers of infection. It is important to recognize that
anti-malaria antibodies acquired as a result of natural infections
can function in various ways, not only by preventing merozoite
invasion and intra-erythrocytic growth as studied here, but also by
binding to malaria proteins expressed on the erythrocyte surface
and thereby facilitating phagocytosis and preventing cytoadhesion
of infected erythrocytes [60,61]. Furthermore, anti-idiotypic
antibodies and immune complexes may develop with repeated
infections and affect GIA levels. In any event, our data suggest that
the mechanisms of protective immunity in children and adults may
differ whereby antibody-mediated processes are more important in
the former than the latter age group. Ongoing studies of MSP-1
specific immunity in Western Kenya are consistent with this since
anti-MSP-1 antibodies appear to predominate in children whereas
adults demonstrate more robust MSP-1 specific T cell immunity
(Moormann, manuscript in preparation).
Comparison of GIA methodologies showed that inhibition
was greater when parasites were allowed to undergo two rather
than one growth cycle, but that measurements of parasitemia,
dialysis of plasma and minor fac t o r ss u c ha sg r o w t hm e d i aa n d
plate configuration did not substantially affect GIA results. On
the other hand, the parasite line used in the GIA greatly affected
the magnitude of plasma mediated growth inhibition. Differ-
ences in growth inhibition levels observed among 3D7, FVO
and D10 are likely related to the high level of parasite antigenic
diversity and the effect of natural selection on pathways involved
in merozoite invasion and blood stage parasite development
[62]. McCallum et al also report differences in the level of serum
inhibition when using different laboratory adapted parasite lines
or parasites that differ by invasion phenotype. Although our
study and that conducted by McCallum et al utilized laboratory
adapted parasite lines, differential growth inhibition by plasma
against various field isolates has been demonstrated [63]. Using
multiple laboratory and/or field isolates may improve the
characterization of plasma growth inhibitory activity for a
population.
Testing the hypothesis that GIA could be used as a marker of
partial protection against blood stage malaria that develops in
residents of malaria holoendemic areas, our results show that
higher levels of growth inhibition activity were associated with a
modest delay in time to infection with age as an important
independent variable. Additionally, a trend was observed that
individuals who were BS negative at baseline had higher GIA
compared to those with positive BS, though this was not
statistically significant. It is important to emphasize that GIA
results likely represent only one of several immune endpoints
that may be considered as surrogates of protection against blood
stage malaria. It is possible that growth inhibitory antibodies
have a more important function in children than adults, an
important consideration in blood stage vaccine endpoint
evaluation. GIA used in blood stage vaccine studies by the
Malaria Vaccine Initiative (MVI) reference laboratory utilizes
purified and concentrated IgG from plasma with one growth
cycle parasitemia measured by pLDH [28,43,64]. Growth
inhibitory activity of plasma is thought to be mediated primarily
by IgG [34,59]. Our use of diluted plasma in GIA may be
comparable to MVI GIA, but our plasma samples were not
tested by the MVI reference laboratory and therefore no
definitive conclusions can be made. Understanding the develop-
ment of parasite growth inhibition within the context of natural
malaria infection and transmission is essential to blood stage
vaccine endpoint evaluation. GIA would not be appropriate for
use with pre-erythrocytic vaccine evaluation unless the targeted
antigen were also highly expressed in the blood stage. Using GIA
as method to predict the risk of malaria disease (our study had
insufficient power for this analysis) and examination of other
malaria-endemic populations is needed to corroborate our
findings and further define the value of GIA as a tool to
evaluate human malaria immunity.
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